Compositions and methods for modulating bone mineral deposition
US7888372B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 28, 2003 |
| Grant date | Feb 15, 2011 |
| Priority date | — |
| Expiry date | Apr 27, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The key function of TNAP in bone is degradation of PPi to remove this mineralization inhibitor and provide free phosphate for apatite deposition. PC-1 is a direct antagonist of TNAP function. ANK also antagonizes TNAP-dependent matrix calcification. Specifically, the activity of PC-1 inhibits initial MV apatite deposition, but ANK inhibits propagation of apatite outside the MVs. Furthermore, loss of function of the two distinct skeletal TNAP antagonists, PC-1 and ANK, ameliorates TNAP deficiency-associated osteomalacia in vivo. Conversely, the hyperossification associated with both PC-1 null mice and ANK-deficient (ank/ank) mice is ameliorated by deficiency of TNAP in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.